GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

AIM Vaccine will rapidly advance the clinical trials of the mRNA respiratory syncytial virus (RSV) vaccine. As a new and globally heavyweight key vaccine product, this product is expected to become a ...

Each year, up to 160,000 older adults living in the United States are hospitalized and as many as 10,000 die due to respiratory syncytial virus (RSV). RSV is a highly contagious virus that spreads ...

The U.S. Food and Drug Administration approved Moderna's RSV vaccine in May. Blake Brittain reports on intellectual property law, including patents, trademarks, copyrights and trade secrets ...

British drugmaker GlaxoSmithKline sued Moderna in US federal ... The US Food and Drug Administration approved Moderna's RSV vaccine in May. GSK said in the new cases that its patents cover ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in ... RNA technology with its blockbuster COVID-19 vaccine Spikevax and RSV shot mResvia. According to the two lawsuits, Moderna's ...

The vaccine was previously approved in Canada for adults aged 60 and over. Credit: MargJohnsonVA/Shutterstock. GlaxoSmithKline (GSK) has received approval for its ...